about
Targeting cancer using KAT inhibitors to mimic lethal knockoutsExploring circulating micro-RNA in the neoadjuvant treatment of breast cancerEvolution of a research field-a micro (RNA) example.Big Data-Led Cancer Research, Application, and Insights.Practical Bioinformatics Analysis of MiRNA Data Using Online Tools.Rational design and validation of a Tip60 histone acetyltransferase inhibitor.Differential impact of hormone receptor status on survival and recurrence for HER2 receptor-positive breast cancers treated with TrastuzumabEffects of age on the detection and management of breast cancer.Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring.ROCK activity and the Gβγ complex mediate chemotactic migration of mouse bone marrow-derived stromal cellsCo-mutation of histone H2AX S139A with Y142A rescues Y142A-induced ionising radiation sensitivity.Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in CancerScreening of exosomal microRNAs from colorectal cancer cells.MCPH1/BRIT1 limits ionizing radiation-induced centrosome amplification.Evaluating the effectiveness of a practical inquiry-based learning bioinformatics module on undergraduate student engagement and applied skills.Advances in Precision Medicine: Tailoring Individualized Therapies.In Vitro Histone Acetylation Assay.Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.Primary cilium-associated genes mediate bone marrow stromal cell response to hypoxia.Correction to: Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options.Quantifying Tip60 (Kat5) stratifies breast cancerCirculating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancerClinically Applicable Inhibitors Impacting Genome StabilityPatent spotlight: small-molecule lysine acetyltransferase inhibitors (KATi)Quantifying Argonaute 2 (Ago2) expression to stratify breast cancerRecent Advances in Understanding FOXN3 in Breast Cancer, and Other Malignancies
P50
Q26741346-8E5D4DD2-A2FB-432B-9B46-13B421914689Q28066481-4D0A5077-8CC3-473F-B4D6-1F17E312F273Q30487729-C6C329F1-4EDE-403D-991C-D07474A294DDQ31140422-B31F5068-7705-4FCF-BCFA-E73B2D42EA0BQ31141560-5AD165EA-3AB5-4ABA-B096-0CC63EA703B2Q33781138-C07D5AF0-5313-40C6-AADE-5AE7FBB7B196Q33843810-875B5CA6-5A2F-4A9F-8A7C-7B8DF121F5C0Q34477879-3A3EE051-4E35-4549-BBE4-79FF3B49F692Q35203556-64D8A708-7008-4094-945B-1574FBA84721Q36156868-EC38ED0B-5629-43CB-8332-68B79DF71B96Q36917479-7AD6AA0E-7B47-465B-BC6F-3BA501A30CDFQ37629542-BBC96B5F-F9FF-4CDD-AFC6-70720E772E4DQ38734531-8D31F49E-2E1F-4253-A06D-892B875AB068Q39675496-8784230E-5407-4F61-AFB6-694872112532Q39780838-71CD7D61-AACC-4F57-B7BF-DCE563ADAA8BQ47160721-9FD42A5D-4E0E-4784-A54F-E5B6DEDC19ACQ47271558-BBA150CA-FF89-429E-ACC8-C564E2744B54Q49796316-E8FCEA10-2282-48C0-A4E5-719BD234EECCQ50637861-6BAB7349-F446-4EAF-AD3D-ECC8229DE9F9Q55265527-93A32583-35FF-400F-9E38-8A92E344AC8CQ64054689-6D25CA9B-6B1C-49B5-93D0-8A723642BF1CQ64057860-870F31BD-32AA-47DB-BDC7-62A99C9C225AQ88661083-DB024404-B4A2-46DF-8C89-328DA5E0DF82Q89487510-94298A08-ED02-4D9A-87A9-6171C74AD1E1Q92029647-90C98EC5-E04B-4713-AAD5-69BD907211A4Q92864376-70EA517E-32C9-4284-9A0E-24D7ABAD9C15
P50
description
cancer researcher
@en
name
James Brown
@ast
James Brown
@de
James Brown
@en
James Brown
@es
James Brown
@fr
James Brown
@gl
James Brown
@it
James Brown
@nl
James Brown
@pt
type
label
James Brown
@ast
James Brown
@de
James Brown
@en
James Brown
@es
James Brown
@fr
James Brown
@gl
James Brown
@it
James Brown
@nl
James Brown
@pt
altLabel
J.A. Brown
@en
J.A.L. Brown
@en
prefLabel
James Brown
@ast
James Brown
@de
James Brown
@en
James Brown
@es
James Brown
@fr
James Brown
@gl
James Brown
@it
James Brown
@nl
James Brown
@pt
P108
P1315
P2038
James_Brown19
P21
P31
P3829
P3835
james-brown54
P496
0000-0002-3155-0334